Family of man who died after being sucked into MRI machine "devastated and seeking answers," lawyers say
Keith McAllister, 61, died after he entered an MRI room at Nassau Open MRI in Westbury last week while a scan was in progress. He was wearing a large metallic chain, and the magnetic force from the machine pulled the chain around his neck, causing him to be drawn in as well and suffer serious injuries, according to Nassau County Police.
McAllister died from those injuries the next day.
According to police, a witness said McAllister defied orders to stay out of the room. He apparently went in after he heard his relative, who was a patient, screaming during a scan.
Attorneys representing the McAllister family released a statement Tuesday.
The McAllister family and their friends are deeply saddened by the tragic loss of Mr. Keith McAllister, who passed away following a preventable incident at Nassau Open MRI in Westbury, New York. We ask the public and friends to keep Mr. McAllister's wife, Adrienne Jones-McAllister, and the entire family in their thoughts and prayers during this profoundly difficult time. The family is truly grateful for the outpouring of heartfelt condolences received from the community and from across the country.
At this time, the focus remains on supporting the McAllister family. Both the family and our team at Smith, Cheung & Lauterborn PC are committed to ensuring that all facts surrounding this incident are thoroughly investigated by the Nassau County Police Department and the New York State Department of Health.
This heartbreaking incident highlights the critical importance of safety protocols in medical imaging facilities. The family and our legal team are dedicated to assisting the appropriate authorities in their investigation and in efforts to ensure accountability and prevent similar tragedies in the future.
The family is devastated and seeking answers.
MRI machines can be especially dangerous for people who require metal objects to be near or on them, such as people who use wheelchairs, oxygen tanks, or those who wear magnetic jewelry.
"It would act like a torpedo trying to get into the middle of the center of the magnet," said Charles Winterfeldt, North Shore University Hospital's director of imaging services.
"The dangers could be catastrophic and it underscores why we have all the safety precautions in place," Dr. Payal Sud said.
Injuries and deaths related to MRI machines pulling in magnetic objects are considered rare.
So far, Nassau Open MRI has declined CBS News New York's request for comment.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
CVS Health tops second quarter expectations and hikes its full-year forecast again
NEW YORK (AP) — CVS Health tops second quarter expectations and hikes its full-year forecast again. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
CVS second-quarter profit beats estimates, helped by medical cost oversight
By Amina Niasse NEW YORK (Reuters) -CVS Health beat Wall Street estimates for second-quarter profit on Thursday, as tight oversight of higher medical costs led to improved performance for its Aetna health insurance business. The company also flagged improved performance in its national pharmacy chain and pharmacy benefit management businesses. CVS reported an adjusted quarterly profit of $1.81 per share, above the average analyst estimate of $1.46 per share, according to LSEG data. For full-year 2025, the insurer raised its profit outlook to $6.30 to $6.40 per share, compared with an average analyst estimate of $6.12 as compiled by LSEG. It attributed the raised forecast to its second-quarter performance. CVS previously had expected full-year earnings per share of $6.00 to $6.20. CVS Health's Aetna insurance business reported a medical loss ratio, or the percentage of premiums spent on medical services, of about 89.9% in the second quarter. Analysts expected a ratio of 91.16%, according to LSEG estimates. It was the third quarter in a row that CVS beat earnings targets as the company works on a turnaround after having missed financial targets repeatedly last year. Those problems had stemmed from an unexpected sharp rise in medical costs in its Medicare Advantage plans for people aged 65 and older or with disabilities, and struggles with its pharmacies. "Nothing is a surprise to us this quarter," said CEO David Joyner in an interview with Reuters. Joyner, who joined the company last October, said the Aetna business experienced higher costs in its Medicare Advantage plans sold through groups such as employers or retiree organizations, but those costs were accurately anticipated. Aetna aims to reprice half of those plans for 2026, he added. CVS plans to close 250 brick-and-mortar pharmacies this year in an effort to cut costs, and the company is reducing its government-sponsored health insurance plans. Rivals including UnitedHealth, Elevance and Centene have detailed higher-than-expected medical costs for the second quarter due to a sicker patient profile and mismatched government payment rates, primarily in Medicaid plans for low-income people. Government payment pressure in Medicare Advantage plans has also squeezed insurer margins this year, with the Centers for Medicare and Medicaid Services changing its calculations of how to reimburse plans for their sickest members. Joyner said CVS's primary care unit for seniors, Oak Street Health, is impacted by these regulatory changes, but the changes are manageable. Revenue for CVS's health services segment, which houses its Caremark pharmacy benefit manager, rose 10.2%, due to a more favorable drug mix and plan renewals from existing clients, the company said. Revenue for the retail-pharmacy and drug-infusion business increased by 12.5% during the second quarter, which Joyner said was aided by increases in prescription volumes filled. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
2 hours ago
- Yahoo
Where Will Pfizer (PFE) Be in 5 Years?
Key Points Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more efficient and growing modestly. Pfizer will likely still be paying a great dividend five years from now. 10 stocks we like better than Pfizer › Five years ago, the eyes of the world were on Pfizer (NYSE: PFE). The big drugmaker was racing to develop a COVID-19 vaccine with its partner, BioNTech (NASDAQ: BNTX). Its stock was poised for a huge gain once that vaccine launched. In general, Pfizer was on the ascent. It's a different story today. Sales for Pfizer's COVID-19 vaccine have declined significantly. The company has encountered clinical setbacks. Its stock has plunged roughly 60% below its late 2021 peak. Pfizer is no longer on the ascent. But where will Pfizer be in five years? Here are five answers to that question. 1. Different top-selling drugs Pfizer's top-selling blockbuster drugs today include blood thinner Eliquis, Prevnar pneumococcal vaccines, its Vyndaqel/Vyndamax franchise targeting cardiomyopathy caused by transthyretin-mediated amyloidosis, and breast cancer drug Ibrance. The list will almost certainly look different in 2030. Eliquis and Prevnar 13 lose U.S. patent protection next year. Ibrance follows suit in 2027. Pfizer hopes to push the loss of exclusivity for Vyndaqel/Vyndamax out to 2028, pending a patent term extension. The company's patent cliff also includes kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, and prostate cancer drug Xtandi, all of which go off-patent within the next two years. Which drugs will fill their shoes? Pfizer already has a successor to Prevnar 13 on the market -- Prevnar 20. Acquisitions and internal R&D have also added other rising stars to its portfolio. 2. A bigger player in oncology One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a bigger player in oncology. Sales for bladder cancer drug Padcev, lung cancer drug Lorbrena, multiple myeloma therapy Elrexfio, and breast cancer drug Talzenna are already growing rapidly. Of the 30 late-stage programs in Pfizer's pipeline, 20 target cancer indications. These programs include several new target indications for existing drugs, such as Elrexfio and Padcev, along with promising new candidates such as atirmociclib. 3. More efficient The Pfizer of 2030 will likely be more efficient than the company today. Pfizer is focusing heavily on optimizing its operations. The company expects savings of around $1.5 billion from the first phase of this effort, which should conclude by the end of 2027. Its overall goal was to achieve cost savings of $4.5 billion. However, Pfizer now thinks the number will be $1.2 billion higher, thanks in part to leveraging automation and artificial intelligence. These operational efficiencies will extend to Pfizer's R&D efforts. Pfizer CEO Albourt Bourla told analysts in April that the company is "intensifying our rigorous commercial assessment and portfolio prioritization from early clinical development." He added that Pfizer will direct its "investment and attention to potential blockbuster or mega-blockbuster" therapies. 4. Bigger and growing modestly Overall, I predict Pfizer will be a bigger company five years from now. I also expect that it will continue to grow beyond then, albeit modestly. Just how big Pfizer will be is hard to say. There's a lot of negativity about the company's prospects baked into its share price, with the stock trading at only 8.3 times forward earnings. However, if this negativity wanes as a result of good news (perhaps from acquisitions or positive earnings surprises), Pfizer's market cap could realistically approach $200 billion by 2030 versus around $137 billion today. 5. Still paying a great dividend I'm confident that Pfizer will still pay a great dividend in 2030. The company's management remains firmly committed to the dividend program. CFO Dave Denton said in the first-quarter earnings call, "[T]he dividend remains a critical component and a key component of our capital allocation strategy." Pfizer's board of directors and executive team realize that the dividend is an important reason investors continue to buy the stock. I doubt they'll do anything to jeopardize the dividend program. Will Pfizer's dividend yield top 7% as it does now? Probably not, at least not if the stock performs relatively well over the next few years as I expect it will. Should you buy stock in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $630,291!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,075,791!* Now, it's worth noting Stock Advisor's total average return is 1,039% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 29, 2025 Keith Speights has positions in Pfizer. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends BioNTech Se. The Motley Fool has a disclosure policy. Where Will Pfizer (PFE) Be in 5 Years? was originally published by The Motley Fool
